FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386466547> ?p ?o ?g. }

• W4386466547 abstract "Abstract In cancer cachexia trials, measures of physical function are commonly used as endpoints. For drug trials to obtain regulatory approval, efficacy in physical function endpoints may be needed alongside other measures. However, it is not clear which physical function endpoints should be used. The aim of this systematic review was to assess the frequency and diversity of physical function endpoints in cancer cachexia trials. Following a comprehensive electronic literature search of MEDLINE, Embase and Cochrane (1990–2021), records were retrieved. Eligible trials met the following criteria: adults (≥18 years), controlled design, more than 40 participants, use of a cachexia intervention for more than 14 days and use of a physical function endpoint. Physical function measures were classified as an objective measure (hand grip strength [HGS], stair climb power [SCP], timed up and go [TUG] test, 6‐min walking test [6MWT] and short physical performance battery [SPPB]), clinician assessment of function (Karnofsky Performance Status [KPS] or Eastern Cooperative Oncology Group‐Performance Status [ECOG‐PS]) or patient‐reported outcomes (physical function subscale of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaires [EORTC QLQ‐C30 or C15]). Data extraction was performed using Covidence and followed PRISMA guidance (PROSPERO registration: CRD42022276710). A total of 5975 potential studies were examined and 71 were eligible. Pharmacological interventions were assessed in 38 trials (54%). Of these, 11 (29%, n = 1184) examined megestrol and 5 (13%, n = 1928) examined anamorelin; nutritional interventions were assessed in 21 trials (30%); and exercise‐based interventions were assessed in 6 trials (8%). The remaining six trials (8%) assessed multimodal interventions. Among the objective measures of physical function (assessed as primary or secondary endpoints), HGS was most commonly examined (33 trials, n = 5081) and demonstrated a statistically significant finding in 12 (36%) trials ( n = 2091). The 6MWT was assessed in 12 trials ( n = 1074) and was statistically significant in 4 (33%) trials ( n = 403), whereas SCP, TUG and SPPB were each assessed in 3 trials. KPS was more commonly assessed than the newer ECOG‐PS (16 vs. 9 trials), and patient‐reported EORTC QLQ‐C30 physical function was reported in 25 trials. HGS is the most commonly used physical function endpoint in cancer cachexia clinical trials. However, heterogeneity in study design, populations, intervention and endpoint selection make it difficult to comment on the optimal endpoint and how to measure this. We offer several recommendations/considerations to improve the design of future clinical trials in cancer cachexia." @default.
• W4386466547 created "2023-09-07" @default.
• W4386466547 creator A5008487561 @default.
• W4386466547 creator A5008599880 @default.
• W4386466547 creator A5010704818 @default.
• W4386466547 creator A5017669406 @default.
• W4386466547 creator A5022213237 @default.
• W4386466547 creator A5022319149 @default.
• W4386466547 creator A5023963187 @default.
• W4386466547 creator A5024191556 @default.
• W4386466547 creator A5024478470 @default.
• W4386466547 creator A5025231459 @default.
• W4386466547 creator A5027514051 @default.
• W4386466547 creator A5028429025 @default.
• W4386466547 creator A5036709171 @default.
• W4386466547 creator A5037229827 @default.
• W4386466547 creator A5039574719 @default.
• W4386466547 creator A5040383132 @default.
• W4386466547 creator A5040583970 @default.
• W4386466547 creator A5044211124 @default.
• W4386466547 creator A5045584219 @default.
• W4386466547 creator A5049902199 @default.
• W4386466547 creator A5050928622 @default.
• W4386466547 creator A5054496507 @default.
• W4386466547 creator A5054617624 @default.
• W4386466547 creator A5057851649 @default.
• W4386466547 creator A5075605363 @default.
• W4386466547 creator A5082418108 @default.
• W4386466547 creator A5084121116 @default.
• W4386466547 creator A5086554206 @default.
• W4386466547 creator A5092761364 @default.
• W4386466547 date "2023-09-06" @default.
• W4386466547 modified "2023-10-15" @default.
• W4386466547 title "Physical function endpoints in cancer cachexia clinical trials: Systematic Review 1 of the cachexia endpoints series" @default.
• W4386466547 cites W1835001492 @default.
• W4386466547 cites W191634815 @default.
• W4386466547 cites W1937966958 @default.
• W4386466547 cites W1968678237 @default.
• W4386466547 cites W1975230416 @default.
• W4386466547 cites W1979666460 @default.
• W4386466547 cites W1979855377 @default.
• W4386466547 cites W1981931946 @default.
• W4386466547 cites W1987892987 @default.
• W4386466547 cites W1993095302 @default.
• W4386466547 cites W1994769053 @default.
• W4386466547 cites W1994836088 @default.
• W4386466547 cites W2002108431 @default.
• W4386466547 cites W2009901885 @default.
• W4386466547 cites W2015526987 @default.
• W4386466547 cites W2023043849 @default.
• W4386466547 cites W2029321962 @default.
• W4386466547 cites W2030594499 @default.
• W4386466547 cites W2050763541 @default.
• W4386466547 cites W2064824453 @default.
• W4386466547 cites W2068008235 @default.
• W4386466547 cites W2079633493 @default.
• W4386466547 cites W2081985673 @default.
• W4386466547 cites W2083081405 @default.
• W4386466547 cites W2091580529 @default.
• W4386466547 cites W2092740524 @default.
• W4386466547 cites W2096657471 @default.
• W4386466547 cites W2108198721 @default.
• W4386466547 cites W2109956558 @default.
• W4386466547 cites W2114488753 @default.
• W4386466547 cites W2115761859 @default.
• W4386466547 cites W2116819815 @default.
• W4386466547 cites W2124028388 @default.
• W4386466547 cites W2124699569 @default.
• W4386466547 cites W2145280166 @default.
• W4386466547 cites W2159909434 @default.
• W4386466547 cites W2163227456 @default.
• W4386466547 cites W2165707746 @default.
• W4386466547 cites W2166056254 @default.
• W4386466547 cites W2168652736 @default.
• W4386466547 cites W2170982929 @default.
• W4386466547 cites W2261630389 @default.
• W4386466547 cites W2278001291 @default.
• W4386466547 cites W2304146082 @default.
• W4386466547 cites W2322957625 @default.
• W4386466547 cites W2401905341 @default.
• W4386466547 cites W2466228288 @default.
• W4386466547 cites W2472194737 @default.
• W4386466547 cites W2492289458 @default.
• W4386466547 cites W2515967691 @default.
• W4386466547 cites W2533678588 @default.
• W4386466547 cites W2568702864 @default.
• W4386466547 cites W2588306553 @default.
• W4386466547 cites W2610831848 @default.
• W4386466547 cites W2611376562 @default.
• W4386466547 cites W2612450492 @default.
• W4386466547 cites W2621124586 @default.
• W4386466547 cites W2623370342 @default.
• W4386466547 cites W2626721982 @default.
• W4386466547 cites W2732570082 @default.
• W4386466547 cites W2774323119 @default.
• W4386466547 cites W2777376354 @default.
• W4386466547 cites W2788888327 @default.
• W4386466547 cites W2789258012 @default.
• W4386466547 cites W2790365889 @default.
• W4386466547 cites W2793886696 @default.

• next